Indoco Remedies Limited

As of June 30, 2026, Indoco Remedies Limited carries a market capitalization of 22.05B, placing it among publicly traded companies globally. Its enterprise value stands at 22.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Indoco Remedies Limited's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Indoco Remedies Limited has 92.16M shares outstanding.

As of June 30, 2026, Indoco Remedies Limited trades at a trailing price-to-earnings ratio of 369.94.

As of June 30, 2026, Indoco Remedies Limited trades at an EV/EBITDA multiple of 8.49 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 22.05B versus a market cap of 22.05B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.90M in revenue per employee across its workforce of 6,304.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Indoco Remedies Limited recorded 47.80M in income tax expense. That works out to an effective tax rate of 60.66, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 78.80M, leaving 56.30M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Indoco Remedies Limited's stock has declined approximately 21.61% over the past 52 weeks. The 50-day moving average sits at 241.45, while the 200-day moving average is 222.53.

Over the twelve months ended June 30, 2026, Indoco Remedies Limited generated 18.28B in revenue and converted that into 56.30M in net income, yielding earnings per share of 0.36. EBITDA reached 2.60B, while operating income came in at 340.10M.

Over the twelve months ended June 30, 2026, Indoco Remedies Limited posted a gross margin of 69.11, reflecting its pricing power and cost economics. The operating margin of 1.86 and net profit margin of 0.31 provide insight into operational efficiency.

Indoco Remedies Limited's most recent stock split took place on May 17, 2012 with a 2:15 split ratio.